SCHEMBL6251489

SCHEMBL6251489

CCc1c(C(=O)O)cnn1-c1nc(-c2ccc(OC)cc2)cs1

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 8/20 0.70
MEN1 O00255 7/20 0.70
KMT2A Q03164 7/20 0.70
NPC1 O15118 6/20 0.70
ATM Q13315 1/20 0.70
KDM4E B2RXH2 5/20 0.52
PTGER4 P35408 1/20 0.52
ALDH1A1 P00352 5/20 0.49
HPGD P15428 3/20 0.49
L3MBTL1 Q9Y468 2/20 0.49
CYP1A2 P05177 2/20 0.49
CYP2C9 P11712 2/20 0.49
MAPT P10636 2/20 0.49
LMNA P02545 2/20 0.49
GAA P10253 1/20 0.49
TDP1 Q9NUW8 1/20 0.49
CYP3A4 P08684 1/20 0.49
CYP2C19 P33261 1/20 0.48
SMN1; SMN2 Q16637 4/20 0.48
MAPK1 P28482 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6255491 0.88 KDM4E (0.59) RAB9AMEN1KMT2ANPC1ATM
SCHEMBL6331924 0.78 KDM4E (0.58) RAB9AMEN1KMT2ANPC1ATM
SCHEMBL6255097 0.77 ALDH1A1 (0.51) RAB9AMEN1KMT2ANPC1ATM
SCHEMBL6251676 0.77 RAB9A (0.46) RAB9AMEN1KMT2ANPC1ATM
SCHEMBL14196465 0.77 ITGB2 (0.74) MEN1KMT2AKDM4EALDH1A1HPGD
SCHEMBL6331731 0.77 RAB9A (0.47) RAB9AMEN1KMT2ANPC1ATM
SCHEMBL6225996 0.76 ALDH1A1 (0.46) RAB9AMEN1KMT2ANPC1ATM
SCHEMBL1199213 0.76 MEN1 (0.65) RAB9AMEN1KMT2ANPC1ATM
SCHEMBL1198394 0.74 MEN1 (0.66) RAB9AMEN1KMT2ANPC1ATM
SCHEMBL6331727 0.74 RAB9A (0.44) RAB9AMEN1KMT2ANPC1ATM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6900219-B2 ABCA-1 elevating compounds CV THERAPEUTICS, INC. (US) 2005-05-31 US disclosed
EP-1513534-A2 COMPOUNDS FOR INCREASING ABCA-1 EXPRESSION USEFUL FOR TREATING CORONARY ARTERY DISEASE AND ATHEROSCLEROSIS CV THERAPEUTICS, INC. (US) 2005-03-16 EP disclosed
US-20030220356-A1 ABCA-1 elevating compounds CV THERAPEUTICS, INC. 2003-11-27 US disclosed
WO-2003084544-A2 COMPOUNDS DOR INCREASING ABCA-1 EXPRESSION USEFUL FOR TREATING CORONARY ARTERY DISEASE AND ATHEROSCLEROSIS CV THERAPEUTICS, INC. (US) 2003-10-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030220356-A1 ABCA-1 elevating compounds ABCD3, ABCE1, ABCB4 RAB9A 2138/4885MEN1 4471/4885KMT2A 3796/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.